

September 2, 2019

Ono Announces Status and Completion of Acquisition of Own Shares

(Acquisition of own shares under the Articles of Incorporation pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Osaka, Japan, September 2, 2019 - Ono Pharmaceutical Co., Ltd. (President, Representative Director, Gyo Sagara; “the Company”) today announced that it has acquired its own shares as set forth below, under the provisions of Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act, and that it has completed the acquisition of its own shares in accordance with the resolution passed on May 30, 2019, pursuant to the provisions of Article 370 of the Companies Act (resolution by documents instead of resolution by board meetings).

Particulars

- | | |
|--|---|
| 1. Class of shares acquired: | Common stock of the Company |
| 2. Total number of shares acquired: | 7,353,000 shares |
| 3. Aggregate amount of acquisition cost: | 14,577,172,450 yen |
| 4. Period of acquisition: | August 1, 2019 to August 30, 2019
(execution base) |
| 5. Method for acquisition: | Purchased on the Tokyo Stock Exchange |

(Reference)

1. Details of the resolution on May 30, 2019 by documents instead of resolution by board meetings
 - (1) Class of shares to be acquired: Common stock of the Company
 - (2) Total number of shares to be acquired: 15 million shares (maximum)
(2.92% of the total outstanding shares excluding treasury shares)
 - (3) Aggregate amount of acquisition cost: ¥30.0 billion (maximum)
 - (4) Period of acquisition: May 31, 2019 to September 30, 2019
2. Accumulated Company’s own shares acquired through August 30, 2019, pursuant to the resolution by documents instead of resolution by board meetings
 - (1) Total number of shares acquired: 15,000,000 shares
 - (2) Aggregate amount of acquisition cost: 29,576,153,400 yen

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

Public_relations@ono.co.jp